JNJ - J&J Phase 3 study shows subcutaneous Tremfya effective in Crohn's
2024-06-20 10:29:07 ET
More on Johnson & Johnson
- Johnson & Johnson (JNJ) Goldman Sachs 45th Annual Global Healthcare Conference (Transcript)
- Johnson & Johnson: Market Will Regret The Overreaction
- Johnson & Johnson (JNJ) Bernstein's 40th Annual Strategic Decisions Conference - (Transcript)
- J&J's Talvey demonstrates robust long-term response in multiple myeloma
- Cancer victims seek court order to block J&J’s bankruptcy bid